Okura A, Naito K, Iizuka H, Ishizuka M, Takeuchi T, Umezawa H
J Biol Response Mod. 1987 Feb;6(1):35-43.
Oral administration of forphenicinol, S-2-(3-hydroxy-4-hydroxymethylphenyl)glycine, inhibited the growth of EL4 lymphoma by both pre- and posttreatment. Although some mice given this drug rejected the tumor, they could not obtain acquired immunity against the tumor. Macrophages taken from normal mice did not inhibit the growth of EL4 cells in vivo (tumor neutralization assay) or in vitro (cytostasis assay). Forphenicinol induced effector activity in such macrophages neither in vitro nor in vivo. Forphenicinol administration to mice bearing EL4 activated macrophages to inhibit the growth of EL4 in vitro and in vivo. Moreover, it stimulated the tumor growth-inhibitory activity of splenocytes in both tumor-free and tumor-bearing mice.
口服福酚美克（S-2-(3-羟基-4-羟甲基苯基)甘氨酸）在治疗前和治疗后均可抑制EL4淋巴瘤的生长。虽然给予这种药物的一些小鼠排斥肿瘤，但它们无法获得针对该肿瘤的获得性免疫。从正常小鼠获取的巨噬细胞在体内（肿瘤中和试验）或体外（细胞生长抑制试验）均未抑制EL4细胞的生长。福酚美克在体外和体内均未诱导此类巨噬细胞产生效应活性。给携带EL4的小鼠施用福酚美克可激活巨噬细胞，从而在体外和体内抑制EL4的生长。此外，它还刺激了无肿瘤和携带肿瘤小鼠脾细胞的肿瘤生长抑制活性。
